This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Izhar Salomon group

Salomon, Izhar.jpg

Izhar Salomon

Ph.D. Student

Personal details


I joined the Linn group in 2012 with a strong background in immunology/cell biology at the NKI.

Tamoxifen, an antagonist of the Estrogen Receptor (ER) is a common treatment for ER positive breast cancer. Additionally, it has been shown to be a modulator of immune cells.

I am involved in a project that studies the role of the immune system in breast cancer outcome and whether certain tumor immune cell infiltrates affect adjuvant tamoxifen efficacy.

Additionally we study lymphocytes from healthy donors, and determine whether tamoxifen induces a different ER binding landscape in lymphocytes.

Share this page